This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aghdam S.G., Ebrazeh M., Hemmatzadeh M., Seyfizadeh N., Shabgah A.G., Azizi G., Ebrahimi N., Babaie F., Mohammadi H.: The role of microRNAs in prostate cancer migration, invasion and metastasis. J. Cell. Physiol., 2019; 234: 9927–9942AghdamS.G.EbrazehM.HemmatzadehM.SeyfizadehN.ShabgahA.G.AziziG.EbrahimiN.BabaieF.MohammadiH.The role of microRNAs in prostate cancer migration, invasion and metastasisJ. Cell. Physiol.20192349927994210.1002/jcp.27948Search in Google Scholar
Alford A.V., Brito J.M., Yadav K.K., Yadav S.S., Tewari A.K., Renzulli J.: The use of biomarkers in prostate cancer screening and treatment. Rev. Urol., 2017; 19: 221–234AlfordA.V.BritoJ.M.YadavK.K.YadavS.S.TewariA.K.RenzulliJ.The use of biomarkers in prostate cancer screening and treatmentRev. Urol.201719221234Search in Google Scholar
Bayraktar R., Van Roosbroeck K., Calin G.A.: Cell-to-cell communication: MicroRNAs as hormones. Mol. Oncol., 2017; 11: 1673–1686BayraktarR.Van RoosbroeckK.CalinG.A.Cell-to-cell communication: MicroRNAs as hormonesMol. Oncol.2017111673168610.1002/1878-0261.12144Search in Google Scholar
Boerrigter E., Groen L.N., Van Erp N.P., Verhaegh G.W., Schalken J.A.: Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. Expert Rev. Mol. Diagn., 2020; 20: 219–230BoerrigterE.GroenL.N.Van ErpN.P.VerhaeghG.W.SchalkenJ.A.Clinical utility of emerging biomarkers in prostate cancer liquid biopsiesExpert Rev. Mol. Diagn.20202021923010.1080/14737159.2019.1675515Search in Google Scholar
Bonci D., Coppola V., Musumeci M., Addario A., Giuffrida R., Memeo L., D’Urso L., Pagliuca A., Biffoni M., Labbaye C., Bartucci M., Muto G., Peschle C., De Maria R.: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med., 2008; 14: 1271–1277BonciD.CoppolaV.MusumeciM.AddarioA.GiuffridaR.MemeoL.D’UrsoL.PagliucaA.BiffoniM.LabbayeC.BartucciM.MutoG.PeschleC.De MariaR.The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activitiesNat. Med.2008141271127710.1016/S0022-5347(09)60542-5Search in Google Scholar
Bonci D., Coppola V., Patrizii M., Addario A., Cannistraci A., Francescangeli F., Pecci R., Muto G., Collura D., Bedini R., Zeuner A., Valtieri M., Sentinelli S., Benassi M.S., Gallucci M. i wsp.: A microRNA code for prostate cancer metastasis. Oncogene, 2016; 35: 1180–1192BonciD.CoppolaV.PatriziiM.AddarioA.CannistraciA.FrancescangeliF.PecciR.MutoG.ColluraD.BediniR.ZeunerA.ValtieriM.SentinelliS.BenassiM.S.GallucciM.A microRNA code for prostate cancer metastasisOncogene2016351180119210.1038/onc.2015.176480347326073083Search in Google Scholar
Bucay N., Bhagirath D., Sekhon K., Yang T., Fukuhara S., Majid S., Shahryari V., Tabatabai Z., Greene K.L., Hashimoto Y., Shiina M., Yamamura S., Tanaka Y., Deng G., Dahiya R., Saini S.: A novel micro-RNA regulator of prostate cancer epithelial-mesenchymal transition. Cell Death Differ., 2017; 24: 1263–1274BucayN.BhagirathD.SekhonK.YangT.FukuharaS.MajidS.ShahryariV.TabatabaiZ.GreeneK.L.HashimotoY.ShiinaM.YamamuraS.TanakaY.DengG.DahiyaR.SainiS.A novel micro-RNA regulator of prostate cancer epithelial-mesenchymal transitionCell Death Differ.2017241263127410.1038/cdd.2017.69552017428498363Search in Google Scholar
Chen D.Q., Yu C., Zhang X.F., Liu Z.F., Wang R., Jiang M., Chen H., Yan F., Tao M., Chen L.B., Zhu H., Feng J.F.: HDAC3-mediated silencing of miR-451 decreases chemosensitivity of patients with metastatic castration-resistant prostate cancer by targeting NEDD9. Ther. Adv. Med. Oncol., 2018; 10: 1758835918783132ChenD.Q.YuC.ZhangX.F.LiuZ.F.WangR.JiangM.ChenH.YanF.TaoM.ChenL.B.ZhuH.FengJ.F.HDAC3-mediated silencing of miR-451 decreases chemosensitivity of patients with metastatic castration-resistant prostate cancer by targeting NEDD9Ther. Adv. Med. Oncol.201810175883591878313210.1177/1758835918783132604867230034549Search in Google Scholar
Chen L., Cao H., Feng Y.: MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1. World J. Urol., 2018; 36: 357–365ChenL.CaoH.FengY.MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1World J. Urol.20183635736510.1007/s00345-017-2143-029204706Search in Google Scholar
Cochetti G., Rossi de Vermandois J.A., Maulà V., Giulietti M., Cecati M., Del Zingaro M., Cagnani R., Suvieri C., Paladini A., Mearini E.: Role of miRNAs in prostate cancer: Do we really know everything? Urol. Oncol., 2020; 38: 623–635CochettiG.Rossi de VermandoisJ.A.MaulàV.GiuliettiM.CecatiM.Del ZingaroM.CagnaniR.SuvieriC.PaladiniA.MeariniE.Role of miRNAs in prostate cancer: Do we really know everything?Urol. Oncol.20203862363510.1016/j.urolonc.2020.03.00732284256Search in Google Scholar
Colden M., Dar A.A., Saini S., Dahiya P.V., Shahryari V., Yamamura S., Tanaka Y., Stein G., Dahiya R., Majid S.: MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. Cell Death Dis., 2018; 8: e2572ColdenM.DarA.A.SainiS.DahiyaP.V.ShahryariV.YamamuraS.TanakaY.SteinG.DahiyaR.MajidS.MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2Cell Death Dis.20188e257210.1038/cddis.2017.15538639328125091Search in Google Scholar
Dong Q., Meng P., Wang T., Qin W., Qin W., Wang F., Yuan J., Chen Z., Yang A., Wang H.: MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One, 2010; 5: e10147DongQ.MengP.WangT.QinW.QinW.WangF.YuanJ.ChenZ.YangA.WangH.MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2PLoS One20105e1014710.1371/journal.pone.0010147285468520418948Search in Google Scholar
Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M., Znaor A., Bray F.: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer., 2019; 144: 1941–1953FerlayJ.ColombetM.SoerjomataramI.MathersC.ParkinD.M.PiñerosM.ZnaorA.BrayF.Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInt. J. Cancer.20191441941195310.1002/ijc.3193730350310Search in Google Scholar
Filella X., Foj L.: miRNAs as novel biomarkers in the management of prostate cancer. Clin. Chem. Lab. Med., 2017; 55: 715–736FilellaX.FojL.miRNAs as novel biomarkers in the management of prostate cancerClin. Chem. Lab. Med.20175571573610.1515/cclm-2015-107326751899Search in Google Scholar
Fu X., Meng Z., Liang W., Tian Y., Wang X., Han W., Lou G., Wang X., Lou F., Yen Y., Yu H., Jove R., Huang W.: miR-26 enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene, 2014; 33: 4296–4306FuX.MengZ.LiangW.TianY.WangX.HanW.LouG.WangX.LouF.YenY.YuH.JoveR.HuangW.miR-26 enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasisOncogene2014334296430610.1038/onc.2013.385487328924056962Search in Google Scholar
Galardi S., Mercatelli N., Giorda E., Massalini S., Frajese G.V., Ciafrè S.A., Farace M.G.: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem., 2007; 282: 23716–23724GalardiS.MercatelliN.GiordaE.MassaliniS.FrajeseG.V.CiafrèS.A.FaraceM.G.miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1J. Biol. Chem.2007282237162372410.1074/jbc.M70180520017569667Search in Google Scholar
Goto Y., Kojima S., Nishikawa R., Enokida H., Chiyomaru T., Kinoshita T., Nakagawa M., Naya Y., Ichikawa T., Seki N.: The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget, 2014; 5: 7748–7759GotoY.KojimaS.NishikawaR.EnokidaH.ChiyomaruT.KinoshitaT.NakagawaM.NayaY.IchikawaT.SekiN.The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancerOncotarget201457748775910.18632/oncotarget.2294420215825115396Search in Google Scholar
Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y., Goodall G.J.: The miR–200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol., 2008; 10: 593–601GregoryP.A.BertA.G.PatersonE.L.BarryS.C.TsykinA.FarshidG.VadasM.A.Khew-GoodallY.GoodallG.J.The miR–200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1Nat. Cell Biol.20081059360110.1038/ncb172218376396Search in Google Scholar
Gu H., Liu M., Ding C., Wang X., Wang R., Wu X., Fan R.: Hypoxia-responsive miR-124 and miR-144 reduce hypoxia-induced autophagy and enhance radiosensitivity of prostate cancer cells via suppressing PIM1. Cancer Med., 2016; 5: 1174–1182GuH.LiuM.DingC.WangX.WangR.WuX.FanR.Hypoxia-responsive miR-124 and miR-144 reduce hypoxia-induced autophagy and enhance radiosensitivity of prostate cancer cells via suppressing PIM1Cancer Med.201651174118210.1002/cam4.664492437626990493Search in Google Scholar
Hao P., Kang B., Yao G., Hao W., Ma F.: MicroRNA-211 suppresses prostate cancer proliferation by targeting SPARC. Oncol. Lett., 2018; 15: 4323–4329HaoP.KangB.YaoG.HaoW.MaF.MicroRNA-211 suppresses prostate cancer proliferation by targeting SPARCOncol. Lett.2018154323432910.3892/ol.2018.7877583585729541199Search in Google Scholar
Hsieh I.S., Chang K.C., Tsai Y.T., Ke J.Y., Lu P.J., Lee K.H., Yeh S.D., Hong T.M., Chen Y.L.: MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis, 2013; 34: 530–538HsiehI.S.ChangK.C.TsaiY.T.KeJ.Y.LuP.J.LeeK.H.YehS.D.HongT.M.ChenY.L.MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathwayCarcinogenesis20133453053810.1093/carcin/bgs37123188675Search in Google Scholar
Hu B., Jin X., Wang J.: MicroRNA-212 targets mitogen-activated protein kinase 1 to inhibit proliferation and invasion of prostate cancer cells. Oncol. Res., 2018; 26: 1093–1102HuB.JinX.WangJ.MicroRNA-212 targets mitogen-activated protein kinase 1 to inhibit proliferation and invasion of prostate cancer cellsOncol. Res.2018261093110210.3727/096504018X15154112497142784474829321092Search in Google Scholar
Kojima S., Enokida H., Yoshino H., Itesako T., Chiyomaru T., Kinoshita T., Fuse M., Nishikawa R., Goto Y., Naya Y., Nakagawa M., Seki N.: The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J. Hum. Genet., 2014; 59: 78–87KojimaS.EnokidaH.YoshinoH.ItesakoT.ChiyomaruT.KinoshitaT.FuseM.NishikawaR.GotoY.NayaY.NakagawaM.SekiN.The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancerJ. Hum. Genet.201459788710.1038/jhg.2013.12124284362Search in Google Scholar
Lin H.M., Nikolic I., Yang J., Castillo L., Deng N., Chan C.L., Yeung N.K., Dodson E., Elsworth B., Spielman C., Lee B.Y., Boyer Z., Simpson K.L., Daly R.J., Horvath L.G., Swarbrick A.: MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer. Sci. Rep., 2018; 8: 7820LinH.M.NikolicI.YangJ.CastilloL.DengN.ChanC.L.YeungN.K.DodsonE.ElsworthB.SpielmanC.LeeB.Y.BoyerZ.SimpsonK.L.DalyR.J.HorvathL.G.SwarbrickA.MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancerSci. Rep.20188782010.1038/s41598-018-26050-y595991129777112Search in Google Scholar
Lin P.C., Chiu Y.L., Banerjee S., Park K., Mosquera J.M., Giannopoulou E., Alves P., Tewari A.K., Gerstein M.B., Beltran H., Melnick A.M., Elemento O., Demichelis F., Rubin M.A.: Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res., 2013; 73: 1232–1244LinP.C.ChiuY.L.BanerjeeS.ParkK.MosqueraJ.M.GiannopoulouE.AlvesP.TewariA.K.GersteinM.B.BeltranH.MelnickA.M.ElementoO.DemichelisF.RubinM.A.Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progressionCancer Res.2013731232124410.1158/0008-5472.CAN-12-2968356373423233736Search in Google Scholar
Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., Patrawala L., Yan H., Jeter C., Honorio S., Wiggins J.F., Bader A.G., Fagin R., Brown D., Tang D.G.: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med., 2011; 17: 211–215LiuC.KelnarK.LiuB.ChenX.Calhoun-DavisT.LiH.PatrawalaL.YanH.JeterC.HonorioS.WigginsJ.F.BaderA.G.FaginR.BrownD.TangD.G.The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44Nat. Med.20111721121510.1038/nm.2284307622021240262Search in Google Scholar
Liu C., Liu R, Zhang D., Deng Q., Liu B., Chao H.P., Rycaj K., Takata Y., Lin K., Lu Y., Zhong Y., Krolewski J., Shen J., Tang D.G.: MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat. Commun., 2017; 8: 14270LiuC.LiuRZhangD.DengQ.LiuB.ChaoH.P.RycajK.TakataY.LinK.LuY.ZhongY.KrolewskiJ.ShenJ.TangD.G.MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genesNat. Commun.201781427010.1038/ncomms14270526424428112170Search in Google Scholar
Liu R.S., Olkhow-Mitsel E., Jeyapala R., Zhao F., Commisso K., Klotz L., Loblaw A., Liu S.K., Vesprini D., Flesher N.E., Bapat B.: Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillance. J. Urol., 2018; 199: 1475–1481LiuR.S.Olkhow-MitselE.JeyapalaR.ZhaoF.CommissoK.KlotzL.LoblawA.LiuS.K.VespriniD.FlesherN.E.BapatB.Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillanceJ. Urol.20181991475148110.1016/j.juro.2017.12.00629246734Search in Google Scholar
Liu Y.N., Yin J.J., Abou-Kheir W., Hynes P.G., Casey O.M., Fang L., Yi M., Stephens R.M., Seng V., Sheppard-Tillman H., Martin P., Kelly K.: Mir-1 and miR-200 inhibit EMT via slug-dependent and tumorigenesis via slug-independent mechanisms. Oncogene, 2013; 32: 296–306LiuY.N.YinJ.J.Abou-KheirW.HynesP.G.CaseyO.M.FangL.YiM.StephensR.M.SengV.Sheppard-TillmanH.MartinP.KellyK.Mir-1 and miR-200 inhibit EMT via slug-dependent and tumorigenesis via slug-independent mechanismsOncogene20133229630610.1038/onc.2012.58758049722370643Search in Google Scholar
Loeb S., Catalona W.J.: The prostate health index: A new test for the detection of prostate cancer. Ther. Adv. Urol., 2014; 6: 74–77LoebS.CatalonaW.J.The prostate health index: A new test for the detection of prostate cancerTher. Adv. Urol.20146747710.1177/1756287213513488394336824688603Search in Google Scholar
Lynch S.M., McKenna M.M., Walsh C.P., McKenna D.J.: miR-24 regulates CDKN1B/p27 expression in prostate cancer. Prostate, 2016; 76: 637–648LynchS.M.McKennaM.M.WalshC.P.McKennaD.J.miR-24 regulates CDKN1B/p27 expression in prostate cancerProstate20167663764810.1002/pros.2315626847530Search in Google Scholar
Majid S., Dar A.A., Saini S., Shahryari V., Arora S., Zaman M.S., Chang I., Yamamura S., Tanaka Y., Chiyomaru T., Deng G., Dahiya R.: miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin. Cancer Res., 2013; 19: 73–84MajidS.DarA.A.SainiS.ShahryariV.AroraS.ZamanM.S.ChangI.YamamuraS.TanakaY.ChiyomaruT.DengG.DahiyaR.miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathwaysClin. Cancer Res.201319738410.1158/1078-0432.CCR-12-2952391032423147995Search in Google Scholar
Massillo C., Dalton G.N., Farré P.L., De Luca P., De Siervi A.: Implications of microRNA dysregulation in the development of prostate cancer. Reproduction, 2017; 154: R81–R97MassilloC.DaltonG.N.FarréP.L.De LucaP.De SierviA.Implications of microRNA dysregulation in the development of prostate cancerReproduction2017154R81R9710.1530/REP-17-032228878093Search in Google Scholar
Mihelich B.L., Maranville J.C., Nolley R., Peehl D.M., Nonn L.: Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. PLoS One, 2015; 10: e0124245MihelichB.L.MaranvilleJ.C.NolleyR.PeehlD.M.NonnL.Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohortPLoS One201510e012424510.1371/journal.pone.0124245439698425874774Search in Google Scholar
Miller K.D., Nogueira L., Mariotto A.B., Rowland J.H., Yabroff K.R., Alfano C.A., Jemal A., Kramer J.L., Siegel R.L.: Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin., 2019; 69: 363–385MillerK.D.NogueiraL.MariottoA.B.RowlandJ.H.YabroffK.R.AlfanoC.A.JemalA.KramerJ.L.SiegelR.L.Cancer treatment and survivorship statistics, 2019CA Cancer J. Clin.20196936338510.3322/caac.2156531184787Search in Google Scholar
Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosowa-Agadjanyan E.L., Peterson A., Noteboom J., O’Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L. i wsp.: Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA, 2008; 105: 10513–10518MitchellP.S.ParkinR.K.KrohE.M.FritzB.R.WymanS.K.Pogosowa-AgadjanyanE.L.PetersonA.NoteboomJ.O’BriantK.C.AllenA.LinD.W.UrbanN.DrescherC.W.KnudsenB.S.StirewaltD.L.Circulating microRNAs as stable blood-based markers for cancer detectionProc. Natl. Acad. Sci. USA2008105105131051810.1073/pnas.0804549105249247218663219Search in Google Scholar
Ortiz-Quintero B.: Cell-free microRNAs in blood and other body fluids, as cancer biomarkers. Cell Prolif., 2016; 49: 281–303Ortiz-QuinteroB.Cell-free microRNAs in blood and other body fluids, as cancer biomarkersCell Prolif.20164928130310.1111/cpr.12262649661227218664Search in Google Scholar
Porkka K.P., Pfeiffer M.J., Waltering K.K, Vessella R.L., Tammela T.L., Visakorpi T.: MicroRNA expression profiling in prostate cancer. Cancer Res., 2007; 67: 6130–6135PorkkaK.P.PfeifferM.J.WalteringK.KVessellaR.L.TammelaT.L.VisakorpiT.MicroRNA expression profiling in prostate cancerCancer Res.2007676130613510.1158/0008-5472.CAN-07-053317616669Search in Google Scholar
Porzycki P., Ciszkowicz E., Semik M., Tyrka M.: Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition. Int. Urol. Nephrol., 2018; 50: 1619–1626PorzyckiP.CiszkowiczE.SemikM.TyrkaM.Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognitionInt. Urol. Nephrol.2018501619162610.1007/s11255-018-1938-2613312730014459Search in Google Scholar
Rajendiran S., Parwani A.V., Hare R.J., Dasgupta S., Roby R.K., Vishwanatha J.K.: MicroRNA–940 suppresses prostate cancer migration and invasion by regulating MEIN1. Mol. Cancer, 2014; 13: 250RajendiranS.ParwaniA.V.HareR.J.DasguptaS.RobyR.K.VishwanathaJ.K.MicroRNA–940 suppresses prostate cancer migration and invasion by regulating MEIN1Mol. Cancer20141325010.1186/1476-4598-13-250424655125406943Search in Google Scholar
Rodríguez M., Bajo-Santos C., Hessvik N.P, Lorenz S., Fromm B., Berge V., Sandvig K., Linȇ A., Llorente A.: Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol. Cancer., 2017; 16: 156RodríguezM.Bajo-SantosC.HessvikN.PLorenzS.FrommB.BergeV.SandvigK.LinȇA.LlorenteA.Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomesMol. Cancer.20171615610.1186/s12943-017-0726-4562979328982366Search in Google Scholar
Ru P., Steele R., Newhall P., Phillips N.J., Toth K., Ray R.B.: miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol. Cancer Ther., 2012; 11: 1166–1173RuP.SteeleR.NewhallP.PhillipsN.J.TothK.RayR.B.miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signalingMol. Cancer Ther.2012111166117310.1158/1535-7163.MCT-12-010022402125Search in Google Scholar
Selth L.A., Das R., Townley S.L., Coutinho I., Hanson A.R., Centenera M.M., Stylianou N., Sweeney K., Soekmadji C., Jovanovic L., Nelson C.C., Zoubeidi A., Butler L.M., Goodall G.J., Hollier B.G., Gregory P.A., Tilley W.D.: A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene, 2017; 36: 24–34SelthL.A.DasR.TownleyS.L.CoutinhoI.HansonA.R.CenteneraM.M.StylianouN.SweeneyK.SoekmadjiC.JovanovicL.NelsonC.C.ZoubeidiA.ButlerL.M.GoodallG.J.HollierB.G.GregoryP.A.TilleyW.D.A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancerOncogene201736243410.1038/onc.2016.18527270433Search in Google Scholar
Shi X.B., Xue L., Ma A.H., Tepper C.G., Gandour-Edwards R., Kung H.J., de Vere-White R.W.: Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene, 2013; 32: 4130–4138ShiX.B.XueL.MaA.H.TepperC.G.Gandour-EdwardsR.KungH.J.de Vere-WhiteR.W.Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cellsOncogene2013324130413810.1038/onc.2012.425411147923069658Search in Google Scholar
Shi X.H., Li X., Zhang H., He R.Z., Zhao Y., Zhou M., Pan S.T., Zhao C.L., Feng Y.C., Wang M., Guo X.J., Qin R.Y.: A five microRNA signature for survival prognosis in pancreatic adenocarcinoma based on TCGA data. Sci. Rep., 2018; 8: 7638ShiX.H.LiX.ZhangH.HeR.Z.ZhaoY.ZhouM.PanS.T.ZhaoC.L.FengY.C.WangM.GuoX.J.QinR.Y.A five microRNA signature for survival prognosis in pancreatic adenocarcinoma based on TCGA dataSci. Rep.20188763810.1038/s41598-018-22493-5595597629769534Search in Google Scholar
Stuopelyte K., Daniunaite K., Bakavicius A., Lazutka J.R., Jankevicius F., Jarmalaite S.: The utility of urine-circulating miRNAs for detection of prostate cancer. Br. J. Cancer, 2016; 115: 707–715StuopelyteK.DaniunaiteK.BakaviciusA.LazutkaJ.R.JankeviciusF.JarmalaiteS.The utility of urine-circulating miRNAs for detection of prostate cancerBr. J. Cancer201611570771510.1038/bjc.2016.233502377227490805Search in Google Scholar
Sun Q., Weng D., Li K., Li S., Bai X., Fang C., Luo D., Wu P., Chen G., Wei J.: MicroRNA-139-5P inhibits human prostate cancer cell proliferation by targeting Notch1. Oncol. Lett., 2018; 16: 793–800SunQ.WengD.LiK.LiS.BaiX.FangC.LuoD.WuP.ChenG.WeiJ.MicroRNA-139-5P inhibits human prostate cancer cell proliferation by targeting Notch1Oncol. Lett.20181679380010.3892/ol.2018.8773601992029963147Search in Google Scholar
Tinay I., Tan M., Gui B., Werner L., Kibel A.S., Jia L.: Functional roles and potential clinical application of miRNA-345-5p in prostate cancer. Prostate, 2018; 78: 927–937TinayI.TanM.GuiB.WernerL.KibelA.S.JiaL.Functional roles and potential clinical application of miRNA-345-5p in prostate cancerProstate20187892793710.1002/pros.2365029748958Search in Google Scholar
Tokudome S., Ando R., Koda Y.: Discoveries and application of prostate specific antigen, and some proposals to optimize prostate cancer screening. Cancer Manag. Res., 2016; 8: 45–47TokudomeS.AndoR.KodaY.Discoveries and application of prostate specific antigen, and some proposals to optimize prostate cancer screeningCancer Manag. Res.20168454710.2147/CMAR.S98326486963727274309Search in Google Scholar
Tomlins S.A., Day J.R., Lonigro R.J., Hovelson D.H., Siddiqui J., Kunju L.P., Dunn R.L., Meyer S., Hodge P., Groskopf J., Wei J.T., Chinnaiyan A.M.: Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur. Urol., 2016; 70: 45–53TomlinsS.A.DayJ.R.LonigroR.J.HovelsonD.H.SiddiquiJ.KunjuL.P.DunnR.L.MeyerS.HodgeP.GroskopfJ.WeiJ.T.ChinnaiyanA.M.Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessmentEur. Urol.201670455310.1016/j.eururo.2015.04.039464472425985884Search in Google Scholar
Van Neste L., Hendriks R.J., Dijkstra S., Trooskens G., Cornel E.B., Jannink S.A., de Jong H., Hessels D., Smit F.P., Melchers W.J., Leyten G.H., de Reijke T.M., Vergunst H., Kil P., Knipscheer B.C. i wsp.: Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur. Urol., 2016; 70: 740–748Van NesteL.HendriksR.J.DijkstraS.TrooskensG.CornelE.B.JanninkS.A.de JongH.HesselsD.SmitF.P.MelchersW.J.LeytenG.H.de ReijkeT.M.VergunstH.KilP.KnipscheerB.C.Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk scoreEur. Urol.20167074074810.1016/j.eururo.2016.04.01227108162Search in Google Scholar
Wang M., Yu W., Gao J., Ma W., Frentsch M., Thiel A., Liu M., Rahman N., Qin Z., Li X.: Micro-RNA-487a-3p functions as a new tumor suppressor in prostate cancer by targeting CCND1. J. Cell Physiol., 2020; 235: 1588–1600WangM.YuW.GaoJ.MaW.FrentschM.ThielA.LiuM.RahmanN.QinZ.LiX.Micro-RNA-487a-3p functions as a new tumor suppressor in prostate cancer by targeting CCND1J. Cell Physiol.20202351588160010.1002/jcp.2907831309555Search in Google Scholar
Wang W., Liu J., Wu Q.: MiR-205 suppresses autophagy and enhances radiosensitivity of prostate cancer cells by targeting TP53INP1. Eur. Rev. Med. Pharmacol. Sci., 2016; 20: 92–100WangW.LiuJ.WuQ.MiR-205 suppresses autophagy and enhances radiosensitivity of prostate cancer cells by targeting TP53INP1Eur. Rev. Med. Pharmacol. Sci.20162092100Search in Google Scholar
Wei J.T., Feng Z., Partin A.W., Brown E., Thompson I., Sokoll L., Chan D.W., Lotan Y., Kibel A.S., Busby J.E., Bidair M., Lin D.W., Taneja S.S., Viterbo R., Joon A.Y. i wsp.: Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J. Clin. Oncol., 2014; 32: 4066–4073WeiJ.T.FengZ.PartinA.W.BrownE.ThompsonI.SokollL.ChanD.W.LotanY.KibelA.S.BusbyJ.E.BidairM.LinD.W.TanejaS.S.ViterboR.JoonA.Y.Can urinary PCA3 supplement PSA in the early detection of prostate cancer?J. Clin. Oncol.2014324066407310.1200/JCO.2013.52.8505426511725385735Search in Google Scholar
Williams L.V., Veliceasa D., Vinokour E., Volpert O.V.: miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS One, 2013; 8: e83991WilliamsL.V.VeliceasaD.VinokourE.VolpertO.V.miR-200b inhibits prostate cancer EMT, growth and metastasisPLoS One20138e8399110.1371/journal.pone.0083991387713624391862Search in Google Scholar
Xu L., Zhong J., Guo B., Zhu Q., Liang H., Wen N., Yun W., Zhang L.: miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1. Tumour Biol., 2016; 37: 12023–12032XuL.ZhongJ.GuoB.ZhuQ.LiangH.WenN.YunW.ZhangL.miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1Tumour Biol.201637120231203210.1007/s13277-016-5058-227164937Search in Google Scholar
Yang Y., Guo J.X., Shao Z.Q.: miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study. Asian Pac. J. Trop. Med., 2017; 10: 87–91YangY.GuoJ.X.ShaoZ.Q.miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental studyAsian Pac. J. Trop. Med.201710879110.1016/j.apjtm.2016.09.01128107872Search in Google Scholar
Yao J., Xu C., Fang Z., Li Y., Liu H., Wang Y., Xu C., Sun Y.: Androgen receptor regulated microRNA miR-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathway. Biochem. Biophys. Res. Commun., 2016; 474: 213–219YaoJ.XuC.FangZ.LiY.LiuH.WangY.XuC.SunY.Androgen receptor regulated microRNA miR-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathwayBiochem. Biophys. Res. Commun.201647421321910.1016/j.bbrc.2016.04.10727109471Search in Google Scholar
Zhang S., Cai J., Xie W., Luo H., Yang F.: miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA. Exp. Ther. Med., 2018; 16: 1499–1504ZhangS.CaiJ.XieW.LuoH.YangF.miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CAExp. Ther. Med.2018161499150410.3892/etm.2018.6296609043130112070Search in Google Scholar
Zhou Y.J., Yang H.Q., Xia W., Cui L., Xu R.F., Lu H., Xue Z., Zhang B., Tian Z.N., Cao Y.J., Xing Z.Y., Yin S., He X.Z.: Down-regulation of miR-605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2. Life Sci., 2017; 190: 7–14ZhouY.J.YangH.Q.XiaW.CuiL.XuR.F.LuH.XueZ.ZhangB.TianZ.N.CaoY.J.XingZ.Y.YinS.HeX.Z.Down-regulation of miR-605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2Life Sci.201719071410.1016/j.lfs.2017.09.02828943214Search in Google Scholar
Zhu Y., Shao S., Pan H., Cheng Z., Rui X.: MicroRNA-136 inhibits prostate cancer cell proliferation and invasion by directly targeting mitogen-activated protein kinase 4. Mol. Med. Rep., 2018; 17: 4803–4810ZhuY.ShaoS.PanH.ChengZ.RuiX.MicroRNA-136 inhibits prostate cancer cell proliferation and invasion by directly targeting mitogen-activated protein kinase 4Mol. Med. Rep.2018174803481010.3892/mmr.2018.841729328468Search in Google Scholar